Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis

Journal of Infection and Chemotherapy

Volumn 10, Issue 2, 2004, Pages 76-85

  Takata, Toshihiko ^a   Aizawa, Kazumasa ^a   Shimizu, Atsuyuki ^a   Sakakibara, Shiro ^a   Watabe, Hiroomi ^a   Totsuka, Kyoichi ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Biapenem; Carbapenem; Pharmacodynamics; Pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

BIAPENEM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; MEROPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; GRAM NEGATIVE INFECTION; INFECTION; LOW DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PREDICTION; PSEUDOMONAS AERUGINOSA;

EID: 2342614286     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-003-0292-0     Document Type: Article

References (30)

1. Craig WA. Pharmacodynamics of antimicrobials in animal models. PK/PD workshop. 2002:42nd ICAAC.
2. Catchpole CR, Wise R, Thornber D, Andrews JM. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992;36:1928-34.
3. Malanoski GJ, Collins L, Wennersten C, Moellering RC Jr., Eliopoulos GM. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1993;37:2009-16.
4. Aldridge KE, Morice N, Schiro DD. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994;38:889-93.
5. Raymond NJ, Bremner DA. The in vitro activity of biapenem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother 1995;35:681-6.
6. Clarke AM, Zemcov SJ. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis 1993;12:377-84.
7. Sader HS, Jones RN. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and broad-spectrum beta-lactam drugs. Eur J Clin Microbiol Infect Dis 1993;12:384-91.
8. Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother 1990;34:994-1000.
9. Yang Y, Testa RT, Bhachech N, Rasmussen BA, Bush K. Biochemical characterization of novel tetrahydrofuranyl 1β-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamase, binding to penicillin binding proteins and permeability properties. Antimicrob Agents Chemother 1999;43:2904-9.
10. Fukazawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T, et al. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992;36:1577-9.
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 20:M7-A5. Fifth Ed. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000.
12. Andes D, Craig WA. Pharmacodynamics of the fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002;46:1665-70.
13. Fantin B, Leggett J, Ebert S, Craig WA. Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 1991;35:1413-22.
14. Saito A, Miura T, Tarao F. Pharmacokinetic study on biapenem. Chemotherapy (Tokyo) 1994;42:277-84.
15. Saito A. Pharmacokinetic study on meropenem. Chemotherapy (Tokyo) 1992;40:276-82.
16. Koyama M, Nakagawa K, Takeda K, Higo K, Okumura K. Phase-one clinical study on ceftazidime. Chemotherapy (Tokyo) 1983;31:146-55.
17. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-8.
18. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001;45:13-22.
19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
20. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
21. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001;45:845-51.
22. Nicolau DP, Onyeji CO, Zhong M, Tessier PR, Banevicius MA, Nightingale CH. Pharmacodynamics assessment of cefprozil against Streptococcus pneumoniae: implication for breakpoint determinations. Antimicrob Agents Chemother 2000;44:1291-5.
23. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determination. Antimicrob Agents Chemother 1998;42:2375-9.
24. Hiraishi T, Miyata A, Hara T, Araake M, Ogawa H. Bactericidal activity of biapenem against various bacteria. Jpn J Antibiot 2001;54:581-95.
25. Sasaki K, Arai T. In vitro postantibiotic effect of biapenem, a new carbapenem antibiotic. Chemotherapy (Tokyo) 1994;42:108-14.
26. Bustamante CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:678-82.
27. Yamashita N, Kawashima K, Nomura K, Takeuchi H, Hikida M, Naruke T. Pharmacokinetics of biapenem in laboratory animals. Chemotherapy (Tokyo) 1994;42:243-50.
28. Sumita Y, Nouda H, Tada E, Kohzuki T, Kato M, Okuda T, et al. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administrated to laboratory animals. Chemotherapy (Tokyo) 1992;40:123-31.
29. Okumura K, Tsuji H, Takeda K, Fukuda I, Nagaki T, Takano M, et al. Absorption, distribution, metabolism and excretion of ceftazidime in mice, rats and rabbits. Chemotherapy (Tokyo) 1983;31:188-98.
30. Hara T, Araake M, Watabe H. Antibacterial activity of biapenem against recent clinical isolates. Jpn J Antibiot 2003;56:138-41.